NCT06102005CompletedPhase 2
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 685
- Locations
- 156
- Primary Endpoint
- Annualized rate of asthma exacerbation events
Study Overview
Brief Summary
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A physician-diagnosed moderate-to-severe asthma for ≥12 months based on GINA guidelines Steps 4 and 5
- •Participants with existing treatment with moderate-to-high doses of ICS therapy for in combination with at least 1 but no more than 2 additional controller medications at least 3 months with a stable dose ≥1 month prior to Visit 1
- •At least 1 asthma exacerbation in the past year, with at least one exacerbation occurring while on treatment with moderate to high doses of ICS therapy
- •ACQ-5 score more than 1.5 at Screening (Visit 1)
Exclusion Criteria
- •Chronic obstructive or other lung diseases (eg, COPD, idiopathic pulmonary fibrosis, etc) which may impair lung function, or another diagnosed pulmonary or systemic disease.
- •Current smoker or former smoker with cessation within 6 months of Screening or history of >10 pack-years. Active vaping of any products and/or marijuana smoking within 6 months of Screening.
- •Participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic steroids within 1 month prior to the Screening
- •Participants who have experienced an upper or lower respiratory tract infection within the 4 weeks prior to Screening
- •For participants on chronic OCS use for the maintenance treatment of asthma: history of a serious infection requiring hospitalization within the past 12 months prior to Randomization (Visit 2).
- •Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening
- •Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Arms & Interventions
Lunsekimig Dose1 interval 1
Experimental
Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 1
Intervention: Lunsekimig (Drug)
Lunsekimig Dose 1 interval 2
Experimental
Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 2
Intervention: Lunsekimig (Drug)
Lunsekimig Dose 2 interval 1
Experimental
Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 1
Intervention: Lunsekimig (Drug)
Lunsekimig Dose 2 interval 2
Experimental
Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 2
Intervention: Lunsekimig (Drug)
Placebo
Placebo Comparator
Participants will receive placebo (subcutaneous injection) according to established dosing intervals corresponding to Dose 1 and Dose 2
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Annualized rate of asthma exacerbation events
Time Frame: From baseline to week 48
Secondary Outcomes
- Change from baseline in pre-bronchodilator (BD) FEV1(From baseline to week 48)
- Change from baseline in post-BD FEV1(From baseline to week 48)
- The absolute change in the percent predicted FEV1 from baseline (pre-BD and post-BD)(From baseline to week 48)
- Proportion of participants with ≥ 0.5-point reduction in ACQ-5 score(From baseline to week 48)
- Change from baseline in ACQ-5 score(From baseline to week 48)
- Change from baseline in FeNO(From baseline to week 48)
- Time to first asthma exacerbation(From baseline to week 48)
- Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit(From baseline to week 48)
- Average number of inhalations per day of short-acting beta 2-agoinst (SABA), Low dose ICS/formoterol or ICS/SABA for symptom relief(From baseline to week 48)
- Proportion of participants with ≥0.5-point reduction in ACQ-6 and ACQ-7 score(From baseline to week 48)
- Serum lunsekimig concentrations(From baseline to week 52)
- Anti-drug antibodies (ADA) against lunsekimig(From baseline to week 52)
- Change from baseline in St. George's Respiratory Questionnaire (SGRQ) scores(From baseline to week 48)
- Proportion of participants with ≥4-point improvement in SGRQ score(From baseline to week 48)
- Change from baseline in Asthma Quality of Life Questionnaire Standardized for 12 years and older (AQLQ{S} +12) scores(From baseline to week 48)
- Proportion of participants with ≥0.5-point improvement in AQLQ(S)+12 domain and total scores(From baseline to week 48)
- Change from baseline in ACQ scores(From baseline to week 48)
- Incidence of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interests (AESIs), serious adverse events (SAEs)(From baseline to week 52)
Investigators
Study Sites (156)
Loading locations...
Similar Trials
Completed
Phase 2
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaAsthmaNCT05421598Sanofi446
Completed
Phase 2
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) AmyloidosisAL AmyloidosisNCT02632786Prothena Biosciences Ltd.129
Terminated
Phase 2
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia AreataAlopecia AreataNCT06444451Sanofi166
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With OsteoarthritisOsteoarthritis of the KneeNCT02067611Lina Xu216
Completed
Phase 2
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityObesity or OverweightNCT06579092AstraZeneca310
Related News
Sanofi's Dual-Target Bispecific Lunsekimig Shows Promise in Phase 2 Respiratory Disease Studies- Sanofi's lunsekimig, a novel bispecific Nanobody targeting TSLP and IL-13, met primary and key secondary endpoints in phase 2 studies for moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps.
- The AIRCULES phase 2b study demonstrated statistically significant and clinically meaningful reduction in asthma exacerbations and improvement in lung function regardless of biomarker status.
- The DUET phase 2a study achieved its primary endpoint of nasal polyp score improvement and key secondary endpoints including nasal congestion scores in CRSwNP patients.
- Lunsekimig was well tolerated across all studies, with the drug now advancing to phase 3 trials for respiratory indications while showing limited efficacy in atopic dermatitis.5 months agoSanofi Advances Respiratory Pipeline with Promising Amlitelimab Data in Heterogeneous Inflammatory Asthma- Sanofi's amlitelimab demonstrated clinically meaningful efficacy in heterogeneous inflammatory asthma, showing over 70% reduction in exacerbations in patients with specific biomarkers at week 60 of the TIDE-Asthma phase 2 study.
- The company is expanding its respiratory portfolio with lunsekimig now targeting chronic rhinosinusitis and COPD alongside asthma, with phase 2 readouts anticipated in 2026.
- Itepekimab, developed in partnership with Regeneron, is broadening its clinical program beyond COPD into chronic rhinosinusitis, with phase 3 readouts in COPD expected in H2 2025.last year